Division of Nephrology, Seattle Children's Hospital, Seattle, WA, USA.
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
Pediatr Transplant. 2020 Sep;24(6):e13753. doi: 10.1111/petr.13753. Epub 2020 Jun 4.
SOT is the treatment of choice for end-stage organ disease. Improved long-term survival after NKSOT has uncovered chronic morbidity including CKD. AKI is common after NKSOT and may be associated with long-term CKD.
We performed a retrospective cohort study looking at AKI and CKD after pediatric heart (n = 109) or liver (n = 112) transplant. AKI was defined using KDIGO creatinine-based criteria. pAKI was AKI ≤ 7 days post-transplant; CKD was eGFR < 60 mL/min/1.73 m by modified Schwartz formula for > 3 months. We looked at the incidence of CKD and the effect of perioperative pAKI on the slope of eGFR post-transplant.
pAKI was seen in 63% (n = 69) after heart and 38% (n = 43) after liver transplant. pAKI was associated with longer ICU and hospital stays. Cumulative incidence (95% CI) of CKD at 60 months post-heart transplant was 40.9% (27.9%-57.1%) in patients with AKI vs 35.8% (17.1%-64.8%) in those without (P = NS). Post-liver transplant, the cumulative incidence of CKD at 60 months was 0% in those without pAKI vs 10% (3.2%-29.3%) in those with (P = .01). Patients with pAKI had lower eGFR at last follow-up.
pAKI and CKD are common after NKSOT. Incidence of CKD is higher in those with pAKI. AKI episodes are associated with a drop in eGFR during follow-up. Identifying patients who have had AKI is an important first step in identifying those at risk of repeated AKI episodes. These patients would benefit from closer monitoring for CKD, lower nephrotoxic drug use, and follow-up with nephrology.
SOT 是治疗终末期器官疾病的首选方法。接受非肾源 SOT(NKSOT)治疗的患者长期生存率提高后,慢性发病率包括慢性肾脏病(CKD)逐渐显露出来。急性肾损伤(AKI)在接受 NKSOT 后很常见,并且可能与长期 CKD 相关。
我们进行了一项回顾性队列研究,观察了儿童心脏(n=109)或肝脏(n=112)移植后的 AKI 和 CKD。AKI 采用 KDIGO 基于肌酐的标准定义。pAKI 是指移植后≤7 天的 AKI;通过改良 Schwartz 公式计算 eGFR<60 mL/min/1.73 m2 且持续>3 个月的 CKD。我们观察了 CKD 的发生率以及围手术期 pAKI 对移植后 eGFR 斜率的影响。
心脏移植后 63%(n=69)和肝脏移植后 38%(n=43)出现 pAKI。pAKI 与 ICU 和住院时间延长相关。心脏移植后 60 个月时,发生 AKI 的患者累积发病率(95%CI)为 40.9%(27.9%-57.1%),无 AKI 的患者为 35.8%(17.1%-64.8%)(P=NS)。肝移植后,无 pAKI 的患者 60 个月时的 CKD 累积发病率为 0%,有 pAKI 的患者为 10%(3.2%-29.3%)(P=0.01)。pAKI 患者的 eGFR 在最后一次随访时较低。
NKSOT 后 pAKI 和 CKD 很常见。pAKI 患者的 CKD 发生率更高。AKI 发作与随访期间 eGFR 下降有关。识别发生过 AKI 的患者是识别有重复 AKI 发作风险的患者的重要第一步。这些患者将受益于更密切的 CKD 监测、降低肾毒性药物的使用,并接受肾病学随访。